CAR-T– tag –
-
The Next Frontier in Hematology: China’s Leadership in CAR-T and CRISPR Gene Editing
Source unknown China Overview China has rapidly emerged as a global leader in hematology, achieving significant breakthroughs in CAR-T cell therapy and CRISPR-based hematopoietic stem cell editing. This rapid ascent is profoundly reshapi... -
Comprehensive Analysis Reveals iPSC Potential in CAR-T Therapy for Cancer, Highlights Key Challenges
Research Journal of Pharmacy and Technology India Overview A comprehensive review analyzes the therapeutic potential and inherent risks of hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells... -
Huazhong University of Science and Technology Tongji Hospital Demonstrates In Vivo CAR-T Therapy, Achieving Cost Reduction and Immune Reset for Multiple Sclerosis
Chosunbiz South Korea Overview A research team at Huazhong University of Science and Technology Tongji Hospital has demonstrated in vivo CAR-T therapy for autoimmune diseases like multiple sclerosis, successfully reducing manufacturing a... -
Winship Cancer Institute Launches Cellular Therapy Initiative, Expanding GMP Manufacturing Capacity for Next-Generation Cancer Treatments
Winship Cancer Institute USA Overview The Winship Cancer Institute has launched a Cellular Therapy Initiative to accelerate the development of next-generation cancer treatments. This initiative significantly expands GMP manufacturing cap... -
Franciscan Health Advances Cancer Care with CAR-T Cell Therapy and Bone Marrow Transplants, Addresses Donor Matching Challenges
Franciscan Health USA Overview Franciscan Health Cancer Center Indiana Blood & Marrow Transplantation is spearheading advancements in cancer treatment through cellular therapies, including CAR-T cell therapy and bone marrow transplan... -
TScan Therapeutics Pivots to In Vivo TCR-T Therapy, Halting Allogeneic Cell Program TSC-101 Amidst Manufacturing Challenges
FirstWord Pharma USA Overview TScan Therapeutics announced a strategic pivot, discontinuing its lead allogeneic cell therapy program, TSC-101, and shifting focus to preclinical in vivo TCR-T candidates for solid tumors, citing funding co... -
Cell and Gene Therapy Sector Shifts to “Execution Discipline” Amidst Manufacturing Platform Scrutiny and Autoimmune CAR-T Safety Concerns
LucidQuest Ventures USA Overview A recent strategic roundup highlights a critical shift in the cell and gene therapy (CGT) sector from platform expansion to "execution discipline," emphasized by Bristol Myers Squibb's termination of its ... -
Novartis Halts Autoimmune CAR-T Trials After Three Patient Deaths, Sparking Safety Debate
Endpoints News USA Overview Novartis has disclosed the deaths of three patients from immune effector cell-associated hemophagocytic lymphohistiocytosis (IEC-HS) complications in clinical trials of its CAR-T cell therapy, rapcabtagene aut... -
Fate Therapeutics Initiates Phase 1/2 Trial for Novel Cell Therapy FT839 in Autoimmune Diseases, Expanding Pipeline
TipRanks.com USA Overview Fate Therapeutics has launched a Phase 1/2 dose-escalation and expansion trial for its novel cell therapy candidate, FT839, in patients with autoimmune diseases. This intravenously administered therapy is design... -
Fate Therapeutics Initiates Phase 2 RECLAIM-LN Trial for Lupus Nephritis with Off-the-Shelf iPSC-Derived CD19 CAR-T Cell Therapy FT819
Seeking Alpha USA Overview Fate Therapeutics has commenced its Phase 2 RECLAIM-LN trial for lupus nephritis, administering the first patient with its iPSC-derived CD19 CAR-T cell therapy, FT819, in an outpatient setting. This marks a sig...
